10/18/2024

Janusmed sex and gender

Janusmed sex and gender – Carfilzomib

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
A A
A A

Carfilzomib

Carfilzomib

Class : A

Show all info

Print

Contact us

  1. Dimopoulos MA, Terpos E, Niesvizky R, Palumbo A. Clinical characteristics of patients with relapsed multiple myeloma. Cancer Treat Rev. 2015;41(10):827-35.

  2. Posch D, Rabitsch W, Wohlfarth P, Leiner M, Porpaczy E, Drach J et al. Gender-Specific Aspects in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation: A Single-Center Experience. Oncology. 2017;93(5):295-301.

  3. Yusuf AA, Natwick T, Werther W, Felici D, Mahue M, Bridges KR et al. A retrospective analysis to examine factors associated with mortality in Medicare beneficiaries newly diagnosed with multiple myeloma. Curr Med Res Opin. 2016;32(12):1989-1996.

  4. Micheli A, Ciampichini R, Oberaigner W, Ciccolallo L, de Vries E, Izarzugaza I et al. The advantage of women in cancer survival: an analysis of EUROCARE-4 data. Eur J Cancer. 2009;45(6):1017-27.

  5. Kyprolis (carfilzomib) DailyMed. DailyMed [www]. US National Library of Medicine. [updated 2018-09-28, cited 2019-01-21].

  6. Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špička I, Oriol A et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142-52.

  7. Jonsson F, Ou Y, Claret L, Siegel D, Jagannath S, Vij R et al. A Tumor Growth Inhibition Model Based on M-Protein Levels in Subjects With Relapsed/Refractory Multiple Myeloma Following Single-Agent Carfilzomib Use. CPT Pharmacometrics Syst Pharmacol. 2015;4(12):711-9.

  8. Iannaccone A, Bruno G, Ravera A, Gay F, Salvini M, Bringhen S et al. Evaluation of Cardiovascular Toxicity Associated with Treatments Containing Proteasome Inhibitors in Multiple Myeloma Therapy. High Blood Press Cardiovasc Prev. 2018;25(2):209-218.

  9. Kyprolis (carfilzomib). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2018-10-18, cited 2019-01-21].

  10. Concise. Kalmar: eHälsomyndigheten. 2015 [cited 2018-12-17.]

  1. Dimopoulos MA, Terpos E, Niesvizky R, Palumbo A. Clinical characteristics of patients with relapsed multiple myeloma. Cancer Treat Rev. 2015;41(10):827-35.
  2. Posch D, Rabitsch W, Wohlfarth P, Leiner M, Porpaczy E, Drach J et al. Gender-Specific Aspects in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation: A Single-Center Experience. Oncology. 2017;93(5):295-301.
  3. Yusuf AA, Natwick T, Werther W, Felici D, Mahue M, Bridges KR et al. A retrospective analysis to examine factors associated with mortality in Medicare beneficiaries newly diagnosed with multiple myeloma. Curr Med Res Opin. 2016;32(12):1989-1996.
  4. Micheli A, Ciampichini R, Oberaigner W, Ciccolallo L, de Vries E, Izarzugaza I et al. The advantage of women in cancer survival: an analysis of EUROCARE-4 data. Eur J Cancer. 2009;45(6):1017-27.
  5. Kyprolis (carfilzomib) DailyMed. DailyMed [www]. US National Library of Medicine. [updated 2018-09-28, cited 2019-01-21].
  6. Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špička I, Oriol A et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142-52.
  7. Jonsson F, Ou Y, Claret L, Siegel D, Jagannath S, Vij R et al. A Tumor Growth Inhibition Model Based on M-Protein Levels in Subjects With Relapsed/Refractory Multiple Myeloma Following Single-Agent Carfilzomib Use. CPT Pharmacometrics Syst Pharmacol. 2015;4(12):711-9.
  8. Iannaccone A, Bruno G, Ravera A, Gay F, Salvini M, Bringhen S et al. Evaluation of Cardiovascular Toxicity Associated with Treatments Containing Proteasome Inhibitors in Multiple Myeloma Therapy. High Blood Press Cardiovasc Prev. 2018;25(2):209-218.
  9. Kyprolis (carfilzomib). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2018-10-18, cited 2019-01-21].
  10. Concise. Kalmar: eHälsomyndigheten. 2015 [cited 2018-12-17.]